{"id":"exenatide-microspheres-for-injection","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide mimics glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon release from alpha cells. The microsphere formulation provides sustained, extended-release delivery over weeks to months, improving glycemic control with less frequent dosing than immediate-release formulations. This mechanism helps reduce postprandial and fasting blood glucose levels in patients with type 2 diabetes.","oneSentence":"Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:02.392Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bydureon"],"phase":"phase_3","status":"active","brandName":"Exenatide Microspheres for Injection","genericName":"Exenatide Microspheres for Injection","companyName":"Xiangya Hospital of Central South University","companyId":"xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exenatide Microspheres for Injection is a treatment being studied for obesity. The mechanism of action of Exenatide Microspheres for Injection is unknown.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-01-27T00:00:00.000Z","mah":"ASTRAZENECA AB","brand_name_local":"BYDUREON","application_number":"NDA022200"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}